IOMUM: Iodine Status Monitoring in PortUguese Pregnant woMen: Impact of Supplementation

Sponsor
Universidade do Porto (Other)
Overall Status
Unknown status
CT.gov ID
NCT04010708
Collaborator
Center for Health Technology and Services Research (Other), NOVA Medical School (Other), Centro Hospitalar De São João, E.P.E. (Other), Hospital de Braga (Other)
1,000
1
34.4
29

Study Details

Study Description

Brief Summary

Data from 2007 regarding iodine status among Portuguese pregnant women indicate this is an iodine deficient population group, with only 16.8% presenting adequate urinary iodine values. This may have serious implications for normal cognitive development of the offspring and a concerning socioeconomic impact. In 2013, concerns by the Portuguese Directorate-General of Health lead to the implementation of a public health policy (nº 011/2013) recommending iodine supplementation during pregnancy. IoMum emerges from this context to monitor and update iodine status in Portuguese pregnant women and to evaluate the effectiveness of the above policy by assessing clinical compliance to iodine supplementation and the impact of iodine supplementation in this vulnerable group. IoMum will update data on iodine nutrition in Portuguese pregnant women, promoting political actions towards the elimination of iodine deficiency and thus to the reduction of nutritional, social and economic inequalities.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Urinary Iodine Concentration Measurement

Study Design

Study Type:
Observational
Anticipated Enrollment :
1000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Iodine Status Monitoring in PortUguese Pregnant woMen: Impact of Supplementation
Actual Study Start Date :
Apr 17, 2018
Anticipated Primary Completion Date :
Sep 30, 2020
Anticipated Study Completion Date :
Feb 28, 2021

Arms and Interventions

Arm Intervention/Treatment
IOMUM

Pregnant women

Diagnostic Test: Urinary Iodine Concentration Measurement
UIC

Outcome Measures

Primary Outcome Measures

  1. 1st trimester urinary iodine concentration [Between gestational weeks 10 and 13 plus 6 days (one timepoint collection - Timepoint 1)]

    Median urinary iodine concentration at 1st trimester of gestation

  2. Rate of compliance to iodine supplementation guideline [Between gestational weeks 10 and 13 plus 6 days (one timepoint collection - Timepoint 1)]

    Rate of compliance to iodine supplementation guideline at 1st trimester of gestation

Secondary Outcome Measures

  1. Change in median iodine-to-creatinine ratio [Up to 31 weeks]

    Change in median iodine-to-creatinine ratio between 1st and 3rd trimesters of gestation

  2. Proportion of pregnant women with insufficient, adequate or excessive iodine intake [Between gestational weeks 10 and 13 plus 6 days (one timepoint collection - Timepoint 1)]

    Classification of pregnant women by urinary iodine concentration levels according to WHO criteria (insufficient, adequate or excessive iodine intake) at 1st trimester of gestation.

  3. Maternal median thyroglobulin [Between gestational weeks 35 and 41 (one timepoint collection - Timepoint 2)]

    Maternal median thyroglobulin at 3rd trimester of gestation

  4. 1st trimester mean sodium excretion [Between gestational weeks 10 and 13 plus 6 days (one timepoint collection - Timepoint 1)]

    Mean sodium excretion at 1st trimester of gestation

  5. 3rd trimester mean sodium excretion [Between gestational weeks 35 and 41 (one timepoint collection - Timepoint 2)]

    Mean sodium excretion at 3rd trimester of gestation

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Pregnant women attending the 1st trimester fetal ultrasound scan, from the 10th to the 13th gestational week.
Exclusion Criteria:
  • Use of Levothyroxine.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Center for Health Technology and Services Research Porto Portugal 4200-319

Sponsors and Collaborators

  • Universidade do Porto
  • Center for Health Technology and Services Research
  • NOVA Medical School
  • Centro Hospitalar De São João, E.P.E.
  • Hospital de Braga

Investigators

  • Principal Investigator: Elisa Keating, PhD, Center for Health Technology and Services Research
  • Principal Investigator: Conceição Calhau, PhD, Center for Health Technology and Services Research

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Universidade do Porto
ClinicalTrials.gov Identifier:
NCT04010708
Other Study ID Numbers:
  • IOMUM
First Posted:
Jul 8, 2019
Last Update Posted:
Jul 8, 2019
Last Verified:
Jul 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jul 8, 2019